Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone317-276-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.56 billion
Profitability
Miscellaneous
Employees38,680
Next Earnings Date10/23/2019 (Confirmed)
OptionableOptionable
Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly And Co's stock symbol?
Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?
Eli Lilly And Co declared a quarterly dividend on Tuesday, June 18th. Investors of record on Thursday, August 15th will be given a dividend of $0.645 per share on Tuesday, September 10th. This represents a $2.58 dividend on an annualized basis and a yield of 2.35%. The ex-dividend date is Wednesday, August 14th. View Eli Lilly And Co's Dividend History.
How were Eli Lilly And Co's earnings last quarter?
Eli Lilly And Co (NYSE:LLY) released its earnings results on Tuesday, July, 30th. The company reported $1.50 EPS for the quarter, topping analysts' consensus estimates of $1.45 by $0.05. The firm had revenue of $5.64 billion for the quarter, compared to analyst estimates of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. Eli Lilly And Co's revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.48 EPS. View Eli Lilly And Co's Earnings History.
When is Eli Lilly And Co's next earnings date?
How can I listen to Eli Lilly And Co's earnings call?
Eli Lilly And Co will be holding an earnings conference call on Wednesday, October 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Eli Lilly And Co issued on next quarter's earnings?
Eli Lilly And Co updated its FY19 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $5.67-5.77 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.66. The company issued revenue guidance of $22-22.5 billion, compared to the consensus revenue estimate of $22.18 billion.
What price target have analysts set for LLY?
15 equities research analysts have issued 12 month price targets for Eli Lilly And Co's stock. Their forecasts range from $74.51 to $143.00. On average, they anticipate Eli Lilly And Co's stock price to reach $122.49 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Price Targets for Eli Lilly And Co.
What is the consensus analysts' recommendation for Eli Lilly And Co?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eli Lilly And Co.
What are Wall Street analysts saying about Eli Lilly And Co stock?
Here are some recent quotes from research analysts about Eli Lilly And Co stock:
- 1. According to Zacks Investment Research, "Lilly beat estimates for earnings in the first quarter. However, Lilly lowered its sales guidance for 2019. Revenue growth in 2019 is expected to be driven by higher demand for its newer drugs including Trulicity, Jardiance, Taltz, Verzenio and new migraine drug, Emgality as some older drugs like Cialis face generic competition. Lilly has made significant pipeline progress in the past year with several positive late-stage data readouts, multiple approvals and regulatory submissions. Lilly also added promising new pipeline assets through business development deals. The stock has outperformed the industry in the past year. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line." (5/21/2019)
- 2. Cantor Fitzgerald analysts commented, ". EPS beat, we maintain our OW rating and 12- month PT of $143. We expect upward earnings revisions to move LLY’s shares higher. This should be driven by sales growth, margin expansion, and pipeline advancements." (4/30/2019)
Has Eli Lilly And Co been receiving favorable news coverage?
Media headlines about LLY stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eli Lilly And Co earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Eli Lilly And Co.
Are investors shorting Eli Lilly And Co?
Eli Lilly And Co saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 12,190,000 shares, a drop of 9.8% from the August 30th total of 13,510,000 shares. Based on an average daily volume of 3,610,000 shares, the short-interest ratio is currently 3.4 days. Currently, 1.4% of the shares of the stock are short sold. View Eli Lilly And Co's Current Options Chain.
Who are some of Eli Lilly And Co's key competitors?
Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Eli Lilly And Co own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly And Co investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Intel (INTC), AT&T (T), General Electric (GE), Bank of America (BAC), Verizon Communications (VZ), Exxon Mobil (XOM) and JPMorgan Chase & Co. (JPM).
Who are Eli Lilly And Co's key executives?
Eli Lilly And Co's management team includes the folowing people:
- Mr. David A. Ricks, Chairman, CEO & Pres (Age 51)
- Mr. Joshua L. Smiley, Sr. VP & CFO (Age 49)
- Dr. Daniel M. Skovronsky, Sr. VP & Chief Scientific Officer (Age 45)
- Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 56)
- Mr. Jeffrey N. Simmons, Sr. VP & Pres of Elanco Animal Health (Age 52)
Who are Eli Lilly And Co's major shareholders?
Eli Lilly And Co's stock is owned by a number of of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (12.08%), Gateway Investment Advisers LLC (0.05%), Bedel Financial Consulting Inc. (0.04%), Private Capital Advisors Inc. (0.03%), Atalanta Sosnoff Capital LLC (0.03%) and Hexavest Inc. (0.03%). Company insiders that own Eli Lilly And Co stock include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.
Which institutional investors are selling Eli Lilly And Co stock?
LLY stock was sold by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Lilly Endowment Inc., Ferguson Wellman Capital Management Inc., Gateway Investment Advisers LLC, Pennsylvania Trust Co, Varma Mutual Pension Insurance Co, Verde Servicos Internacionais S.A. and Gradient Investments LLC. Company insiders that have sold Eli Lilly And Co company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry. View Insider Buying and Selling for Eli Lilly And Co.
Which institutional investors are buying Eli Lilly And Co stock?
LLY stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Private Capital Advisors Inc., Country Trust Bank, First National Bank of Mount Dora Trust Investment Services, TIAA FSB, Enterprise Bank & Trust Co, Exane Derivatives and Pacer Advisors Inc.. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and Joshua L Smiley. View Insider Buying and Selling for Eli Lilly And Co.
How do I buy shares of Eli Lilly And Co?
Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Eli Lilly And Co's stock price today?
One share of LLY stock can currently be purchased for approximately $109.70.
How big of a company is Eli Lilly And Co?
Eli Lilly And Co has a market capitalization of $105.91 billion and generates $24.56 billion in revenue each year. The company earns $3.23 billion in net income (profit) each year or $5.55 on an earnings per share basis. Eli Lilly And Co employs 38,680 workers across the globe.View Additional Information About Eli Lilly And Co.
What is Eli Lilly And Co's official website?
How can I contact Eli Lilly And Co?
Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
